Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study

[11] Martinez-Baz I(1998)Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants Pediatrics 102 275-1981

[12] Moreno-Galarraga L(2016)Population-based analysis of bronchiolitis epidemiology in Valencia Spain Pediatr Infect Dis J 35 1883379-425

[13] Zhang S(2022)Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017 Hum Vaccin Immunother 18 1975-846

[14] Akmar LZ(2012)Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis Eur J Clin Microbiol Infect Dis 31 759-1179

[15] Bailey F(2022)Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study BMC Infect Dis 22 415-189

[16] Hall CB(2020)Single-dose nirsevimab for prevention of RSV in preterm infants N Engl J Med 383 837-894

[17] Weinberg GA(2022)Nirsevimab for prevention of RSV in healthy late-preterm and term infants N Engl J Med 386 1172-505

[18] Iwane MK(2023)Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants Nat Med 29 180-S292

[19] Bont L(2023)Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials Lancet Child Adolesc Health 7 892-undefined

[20] Steijn M(2022)Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity N Engl J Med 386 CD006602-undefined

[11] Martinez-Baz I(1998)Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants Pediatrics 102 275-1981

[12] Moreno-Galarraga L(2016)Population-based analysis of bronchiolitis epidemiology in Valencia Spain Pediatr Infect Dis J 35 1883379-425

[13] Zhang S(2022)Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017 Hum Vaccin Immunother 18 1975-846

[14] Akmar LZ(2012)Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis Eur J Clin Microbiol Infect Dis 31 759-1179

[15] Bailey F(2022)Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study BMC Infect Dis 22 415-189

[16] Hall CB(2020)Single-dose nirsevimab for prevention of RSV in preterm infants N Engl J Med 383 837-894

[17] Weinberg GA(2022)Nirsevimab for prevention of RSV in healthy late-preterm and term infants N Engl J Med 386 1172-505

[18] Iwane MK(2023)Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants Nat Med 29 180-S292

[19] Bont L(2023)Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials Lancet Child Adolesc Health 7 892-undefined

[20] Steijn M(2022)Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity N Engl J Med 386 CD006602-undefined